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Objective: rs12576775 was found to be associated with bipolar disorder (BD) in a 
genome- wide association study (GWAS). The GWAS signal implicates genes for the 
microRNAs miR- 708 and miR- 5579 and the first exon of the Odd Oz/ten- m homolog 
4 gene (ODZ4). In the present study, miR- 708, its surrounding region, and its targets 
were analyzed for potential BD- associated functional variants.
Methods: The miR- 708 gene and surrounding regions were screened for variation 
using high- resolution melting (HRM) analysis in 1099 cases of BD, followed by geno-
typing of rare variants in an enlarged sample of 2078 subjects with BD, 1303 subjects 
with schizophrenia, and 1355 healthy controls. Whole- genome sequencing data from 
99 subjects with BD were analyzed for variation in potential miR- 708 binding sites. 
The minor allele frequencies (MAFs) of these variants were compared with those re-
ported in reference individuals.
Results: Three variants detected by HRM were selected to be genotyped. rs754333774 
was detected in three cases of BD, two cases of schizophrenia, and no controls. This 
variant is located 260 base pairs upstream from miR- 708 and may play a role in control-
ling the expression of the miR. Four variants were identified in miR- 708 targets binding 
sites. The MAFs of each of these variants were similar in BD and reference samples.
Conclusions: We report a single recurrent variant located near the miR- 708 gene that 
may have a role in BD and schizophrenia susceptibility. These findings await replica-
tion in independent cohorts, as do functional analyses of the potential consequences 
of this variant.
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O R I G I N A L  A R T I C L E
Genetic variation in the miR- 708 gene and its binding targets 
in bipolar disorder
Alessia Fiorentino1,2 | Niamh Louise O’Brien1 | Sally Isabel Sharp1 | 
David Curtis3,4 | Nicholas James Bass1 | Andrew McQuillin1
Bipolar disorder (BD) is a common disease with a worldwide average 
population prevalence of 1.4%, which rises to 2.4% if bipolar spec-
trum disorders are included.1 BD is strongly familial, with a 10- fold 
increase in risk to the relatives of BD probands.2 Estimates of the 
heritability of BD range from 79% to 93%.3–6 Genome- wide associa-
tion studies (GWAS) have identified a number of common polymor-
phisms which are convincingly associated with BD.7,8 The Psychiatric 
GWAS Consortium Bipolar Disorder (PGC- BD) working group per-
formed a combined analysis of GWAS data from 7481 individuals 
with BD and 9250 controls. The same group also tested 34 single- 
nucleotide polymorphisms (SNPs), that were associated with P- values 
of <5 × 10−5 in the discovery sample, in an independent replication 
cohort of 4496 cases with BD and 42 422 controls. The combined 
analysis of the discovery and replication samples confirmed genome- 
wide significant (GWS) evidence of an association between BD and 
the calcium voltage- gated channel subunit alpha1C gene (CACNA1C), 
and identified a GWS intronic variant in the Odd Oz/ten- m homolog 
4 gene (ODZ4; also known as tenascin- M4 [TENM4]), rs12576775 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
2  |     Fiorentino et al.
(P=4.4 × 10−8).9 Both Green et al.10 and Mühleisen et al.11 later 
showed further evidence for an association between BD and the same 
SNP (P=6.20 × 10−9 and 4.46 × 10−9, respectively). A large intergenic 
region distal to rs12576775 and a proximal genomic region with a high 
recombination rate in intron 1 of ODZ4 effectively restrict the BD as-
sociation region to the genomic interval that includes the first exon 
of ODZ4 and the microRNA (miRNA) genes miR- 708 and miR- 5579.9 
Of the two miRNA genes, only miR- 708 has been experimentally vali-
dated and it is known to be expressed in the human nervous system.12
The role of miRNAs in psychiatric disorders has recently become 
prominent as a result of findings in schizophrenia (SCZ). The PGC-SCZ 
working group reported GWS with a SNP association in the third intron 
of the primary transcript of miR- 137.13 There is evidence that genetic 
variation in this gene influences the negative symptoms of SCZ.14 In 
addition to the findings with miR- 137, several other microRNAs have 
also been implicated in susceptibility to SCZ, including an association 
with miR- 206 (rs17578796) in a Scandinavian sample15 and with miR- 
30e (rs112439044) in a Han Chinese sample.16 Eight ultra- rare variants 
in the precursor or mature microRNA sequences have been reported 
in American males suffering from SCZ.17 An enrichment of rare copy 
number variations (CNVs) overlapping with microRNAs has also been 
reported in SCZ, with 25 microRNAs impacted by rare CNVs in two or 
more unrelated subjects.18 Several studies have investigated polymor-
phic microRNA binding sites in target genes related to SCZ. These in-
clude rs3822674, which is located in the 3ʹ untranslated region (UTR) 
of the gene encoding complexin II (CPLX2) and is predicted to interfere 
with repression of CPLX2 expression by miR- 49819; rs1130354 in the 
3ʹUTR of dopamine receptor D2 gene (DRD2) was reported to inter-
fere with miR- 326- mediated repression of DRD2 expression20; and 
rs11122396 in the 3ʹ UTR of the disrupted- in- schizophrenia- 1 (DISC1) 
gene disrupted miR- 135b- 5p- mediated control of DISC1 expression.21
The evidence that implicates miRNAs in the etiology of BD is not as 
strong as it is for SCZ. However, recent data have provided increasing sup-
port for the hypothesis that miRNAs also play a role in the etiology of BD. 
In the largest GWAS of BD to date, a SNP in an intergenic region flanking 
miR- 2113 on chromosome 6q16.1 was the eighth strongest finding.11 A 
gene- based analysis of all known autosomal microRNAs using the same 
GWAS data found a significant association between nine microRNAs 
(including miR- 708) and BD.22 In another study, bioinformatic analysis 
suggested that the BD- associated glutamate receptor- 7 gene (GRM7) 3ʹ 
UTR variant, rs56173829, might modulate the binding of several microR-
NAs, including miR- 4295, miR- 130a- 3p, and miR- 130b- 3p.23
Postmortem transcriptome studies have shown significant differ-
ences between miRNA expression levels in cortical brain tissue from 
people with BD and controls. While there is substantial heterogeneity 
in the miRNAs that have been reported to be associated with BD, sev-
eral miRNAs have been reported in multiple studies.24
Two main studies have focused on miRNAs levels in the context of 
treatment with mood stabilizers in human tissue. One was conducted 
in lymphoblastoid cell lines, to assess the impact of lithium on miRNA 
expression.25 Of the 13 miRNAs previously suggested to respond to 
lithium and valproate, the regulation of four (miR- 34a- 5p, miR- 152- 3p, 
miR- 155- 5p, miR- 221- 3p) was changed after 16 days of treatment. The 
overall change in miRNA expression was small and no miRNA expres-
sion underwent a two- fold change. A second study focused on miR- 
134- 5p. A decrease in miR- 134- 5p plasma levels was observed during 
manic phases, which correlated with symptom severity. This decrease 
was reversed upon successful treatment with various mood stabiliz-
ers.26 Thus, mood stabilizers used for the treatment of BD may influ-
ence psychopathology through the modification of miRNA biogenesis.
Bioinformatic analyses indicate that miR- 708 is conserved in mam-
mals within the ODZ4 intron, suggesting that miR- 708 is co- expressed 
with ODZ4. The high level of conservation across mammalian species 
of the miR- 708 precursor stem loop and the guide strand suggests 
that they are functionally important. It has been demonstrated that the 
expression of miR- 708 correlates well with the expression of ODZ4 in 
adult mouse tissues. The observation of a significant accumulation of 
miR- 708 and ODZ4 transcripts in the brain and eyes strongly suggests a 
physiological role for miR- 708 in tissues in which ODZ4 is expressed.27 
A study of postpartum psychosis (a disorder that is prevalent in up to 
74% of women with an existing diagnosis of BD and a family history 
of puerperal psychosis28) suggested differential expression of miR- 708 
in the monocytes of affected patients compared with controls.29 miR- 
708 expression has been demonstrated to be upregulated significantly 
in mouse hippocampal neurons in an oxidative stress cell model.30
In the present study, miR- 708, its surrounding region, and its tar-
gets were analyzed for possible functional variants associated with BD.
1  | MATERIALS AND METHODS
1.1 | Subjects
The study included 2078 research subjects with bipolar I (BD- I) or bi-
polar II disorder and 1303 research subjects with SCZ. The University 
College London (UCL) control sample included 1355 subjects, compris-
ing 875 screened subjects who had no first- degree family or personal 
history of psychiatric illness, and an additional 480 unscreened normal 
British subjects obtained from the European Collection of Cell Cultures. 
National Health Service (NHS) multicentre research ethics approval was 
obtained. All participants provided informed written consent. Ancestry 
screening was used as a selection criterion for the inclusion of cases. 
Samples were included if at least three out of four grandparents were 
English, Irish, Scottish, or Welsh, and if the fourth grandparent was non- 
Jewish European, before the EU enlargement in 2004. Participants with 
BD were interviewed using the lifetime version of the Schizophrenia and 
Affective Disorder Schedule.18 Participants fulfilling the research diag-
nostic criteria31 for BD were included. An analogous protocol was used to 
recruit participants with SCZ. Blood or saliva samples were collected for 
all participants. DNA from blood samples was extracted using a standard 
phenol- chloroform method and from saliva samples using the Oragene 
protocol for DNA extraction (DNA Genotek, Ottowa, ON, Canada).
1.2 | Detection and evaluation of new variants
High- resolution melting (HRM) variant screening was used to iden-
tify BD susceptibility variants 300 base pairs (bp) upstream and 
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downstream from the mir-708 gene (chr11:79112766- 79113453, 
GRCh37/hg19).
This method of variant analysis allows cost- efficient detection 
of rare variations in large numbers of samples. HRM is particularly 
amenable to regions not efficiently targeted by established next gen-
eration sequencing selection panels such as introns and UTRs.
HRM was performed using three primer pairs in 1099 cases with 
BD. Reactions were carried out on a LightCycler 480 (Roche, Burgess 
Hill, UK). Primer sequences and reagents are shown in Table S1. 
Samples with abnormal HRM curves were then sequenced using the 
BigDye terminator v3.1 Cycle Sequencing kit (Applied Biosystems, 
Warrington, UK) on an ABI 3730xl DNA Analyzer (Applied Biosystems). 
Sequencing data were analyzed using the Staden Package (http://sta-
den.sourceforge.net/).32 The  reference minor allele frequency (MAF) 
for the general population was evaluated in the data from the 1000 
Genomes (1000G) project,33 in the Exome Aggregation Consortium 
(ExAC), Cambridge, MA, USA (http://exac.broadinstitute.org [accessed 
January 2016]), from the Scripps Wellderly study (n = 534)34 and 
from two population cohorts in the UK10K study (UK10K ALSPAC 
[Avon Longitudinal Study of Parents and Children] and UK10K TWINS 
[TwinsUK n = 2432]).35 The latter two datasets were queried using 
the Reference Variant Store, (http://rvs.u.hpc.mssm.edu [accessed 5 
August 2016]).
For the ExAC data, it is important to take into consideration the 
presence of BD and SCZ diagnoses in the database. This did not affect 
our study because the reported MAFs of the miR- 708 variants selected 
did not exceed our exclusion threshold for genotyping. Bioinformatic 
analysis to determine the potential functional effect of SNPs was car-
ried out using the University of California, Santa Cruz genome browser 
(http://genome.ucsc.edu/), Alibaba 2 (http://www.gene-regulation.
com/pub/programs/alibaba2/index.html) and PROMO using version 
8.3 of TRANSFACT (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/
promoinit.cgi?dirDB=TF_8.3).
Only variants with a MAF lower than 0.01 in the general popula-
tion were considered for further analysis.
1.3 | Genotyping
Genotyping of the selected SNPs was performed in an enlarged sam-
ple of 2078 cases with BD and 1355 ancestrally matched controls. It 
was performed in- house using the allele- specific polymerase chain re-
action (PCR), using KASPar reagents (LGC Genomics, Hoddesdon, UK) 
on a LightCycler 480 real- time PCR machine. Allele- specific primers 
were designed for each of the SNPs using Primer Picker (KBiosciences, 
LGC Genomics, Hoddesdon, UK; primer sequences are listed in Table 
S2). The variants were also genotyped in 1305 SCZ samples. For all 
SNPs, 97% of samples were successfully genotyped. Genotyping for 
each heterozygote sample was repeated at least twice. All of these 
data were analyzed to confirm Hardy- Weinberg equilibrium. Allelic 
associations for SNPs were performed using Fisher’s exact test. 
Significance values shown for all analyses are uncorrected for multiple 
testing, and a cut- off significance value of P<.05 was used.
TABLE  1 SNPs detected by HRM across the region chr11:79112766- 79113453 (GRCh37/hg19); variants: the base change indicated is on 
the—strand; the genomic reference sequence used is GRCh37/hg19; 1000G, 1000genome project; Eur, European population; Exac, Exome 
Aggregation Consortium; Wellderly, Scripps Wellderly study; UK10K, UK10K ALSPAC (Avon Longitudinal Study of Parents and Children) and 
TWINS (TwinsUK); MAF, minor allele frequency; nd, not detected
SNP
Position in 
ch11 Variants
1000G 
MAF
Eur 1000G 
MAF
Exac  
MAF
Eur Exac 
MAF
Wellderly 
MAF
UK10K 
MAF
Position compared 
to miR- 708
rs754333774 79113407 G > A nd nd nd nd 0.000 94 nd Upstream
rs768049399 79113040 A > C nd nd 0.000 064 0.000 097 nd nd Downstream
rs56158925 79112878 C > T 0.082 0.082 nd nd 0.069 29 0.063 54 Downstream
TABLE  2 Genotype counts of microRNA miR- 708 variants in the University College London bipolar disorder (BD) and schizophrenia (SCZ) 
case–control sample
Position on ch11
Position compared with 
miR- 708 Change N Genotype counts MAF
rs754333774 79113407 Upstream G>A 2041 BD 0/3/2038 0.0007
1261 SCZ 0/2/1259 0.0008
3302 BD + SCZ 0/5/3297 0.0007
1310 CTRL 0/0/1310 0
rs768049399 79113040 Downstream A>C 2001 BD 0/1/2000 0.0002
1274 SZ 0/0/1274 0
3275 BD + SCZ 0/1/3274 0.0001
1308 CTRL 0/1/1307 0.0004
BD, bipolar disease; CTRL, control; MAF, minor allele frequency; N, total number; SCZ, schizophrenia. The genomic reference sequence used is GRCh37/
hg19; change: the nucleotide change indicated is on the negative strand; genotype count: number of homozygotes for the minor allele/heterozygotes/ 
homozygotes for the major allele.
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1.4 | Detection and evaluation of variants in the has- 
miR- 708 binding sites
Whole- genome sequencing (WGS) was performed on 99 of the 
subjects with BD- I selected from our BD cohort first on the basis 
of  individuals with a strong positive family history of BD or bipolar 
spectrum disorder. Where the strength of the family history was tied, 
individuals with the earliest age at onset were selected. The mean age 
of onset for the cases selected for sequencing was 21.55 (standard 
deviation [SD] 8.90), and this was significantly lower than the total 
cohort (P = .0124). The genomic DNA was sequenced using 100 bp 
paired- end reads on a Hi- Seq 1000 (Illumina Inc., San Diego, CA, USA). 
Sequence data alignment to the National Center for Biotechnology 
Information human reference genome 37.1 (hg19) and variant calling 
was performed using the CASAVA 1.8.2 pipeline at Illumina (http://
support.illumina.com/sequencing/sequencing_software/casava.
html). The sequence data from these individuals was further analyzed 
and annotated using kGAP (Knome Inc., Boston, MA, USA).36 The BD 
WGS data was screened for variants in miR- 708 binding sites (15 bp 
upstream and 1 bp downstream the microRNA seed) predicted by 
Targetscan 6.2: June 2012 (http://www.targetscan.org/).
1.5 | Imputation and analysis of BD GWAS data
UCL BD and control GWAS data were included in the PGC- BD data-
set.37 These data have been subjected to a standardized quality control 
and imputation pipeline (https://sites.google.com/a/broadinstitute.
org/ricopili/). Association testing was performed using PLINK2.38
2  | RESULTS
2.1 | Variant selection and genotyping
Three single nucleotide variants were detected by HRM analysis across 
the region selected to be analyzed: rs56158925, rs754333774, and 
rs768049399 (Table 1). rs56158925 is located 200 bp downstream 
from mir- 708. This variant has an overall MAF of 0.082 in the general 
population of the 1000G Project, and the same frequency in the data 
from the European subpopulation of the project and with a slightly 
lower frequency in the Wellderly and UK10K cohorts data (Table 1). 
The other two variants, rs754333774 and rs768049399, are located 
260 bp upstream and 27 bp downstream, respectively, of the mir-708 
gene. rs768049399 was annotated in the ExAC database, with an over-
all MAF of 6.4 × 10−5 and 9.7 × 10−5 in the European sub population 
of the project but was not reported in data from the 1000G project, 
Wellderly subjects or in the UK10K cohorts. rs754333774 was also not 
reported in the 1000G project or in the UK10K cohorts however it was 
detected in one of 534 individuals from the Wellderly sample (Table 1). 
The estimated MAF of this variant in these two datasets is 0.0017.
Genotyping assays were designed for the two SNPs with MAFs 
lower than 0.01 in the general population. Genotyping was conducted 
in the complete UCL case–control sample, including cases with BD 
and SCZ. The rs768049399 variant allele was detected in one case 
with BD and in one control (Table 2). The rs754333774 variant allele T
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was detected in three cases with BD, two cases with SCZ, and no con-
trols (Table 2).
Bioinformatic transcription factor binding analysis of the effect of 
rs754333774 did not identify consistent predictions for altered bind-
ing. By contrast, the variant allele of rs768049399 was predicted to 
destroy a binding site for the CCAAT/enhancer- binding protein beta 
transcription factor and to create a binding site for five transcriptional 
factors: hepatocyte nuclear factor (HNF)- 3α; TATA box- binding pro-
tein; homeobox protein D8; HNF- 1C; and HNF1- B.
2.2 | Variants in miR- 708 binding sites
Targetscan 6.2 predicted 4377 transcripts with miR- 708 binding sites 
(including many transcripts with overlapping 3ʹ UTRs), with a total of 
381 conserved sites and 4999 poorly conserved sites (including many 
overlapping sites). These binding sites were analyzed in WGS from 
99 subjects with BD for possible variants. Only four nonreference 
(GRCh37/hg19) allelic variants were identified. The variants were 
located in the genes encoding the following proteins: apolipoprotein 
C- III (APOC3); polypeptide N- acetylgalactosaminyltransferase 13 
(GALNT13); ST6 (alpha- N- acetyl- neuraminyl- 2,3- beta- galactosyl- 1,3)- 
N- acetylgalactosaminide alpha- 2,6- sialyltransferase 4 (ST6GALNAC4); 
and solute carrier family 22 member 23 (SLC22A3) (Table 3). All four 
variants are known common variants that have been annotated on 
The Single Nucleotide Polymorphism Database (dbSNP). rs5128 in 
APOC3 is 1 bp upstream from the miR- 708 seed sequence, while 
the other three variants rs707082, rs1043026, rs5873874, located 
in GALNT13, ST6GALNAC4 and SLC22A3, respectively, are within the 
seed sequence of the miR- 708 binding sites.
The allele frequencies of the four variants in the BD WGS sam-
ples were similar to those reported in both the entire sample and 
the European- only sample from the 1000G project (Table 3). Data 
were available only for rs5128 in the ExAC database, and these 
were similar to those of the BD WGS sample. The 3ʹ UTRs of the 
remaining genes were not included in the exome sequencing data 
in the ExAC database. Association testing of GWAS data for the 
first 491 UCL BD cases and 495 UCL controls, imputed using the 
1000G project data as a reference panel, did not show evidence for 
involvement of rs5128 or rs707082 with BD (P=.5214 and .4286, 
respectively); rs1043026 and rs5873874 were not reliably imputed 
(Table S3).
3  | DISCUSSION
The potential role of miRNAs in psychiatric disorders has recently 
been highlighted by GWS association findings with SNPs within 
miR- 137 and SCZ.13 Several reports have implicated microRNAs 
in BD, both genetically and biologically.11,23,25,26,39,40 The PGC- BD 
group performed a combined analysis of GWAS data that iden-
tified a GWS intronic variant in ODZ4 (TENM4), rs12576775.9 
This  association has been confirmed by two other independent 
studies.10,11
The two variants in miR- 708 with a MAF lower than 0.01 
(rs768049399 and rs754333774) were genotyped in our BD and con-
trol cohorts. The strong prior findings with miRNA genes in SCZ led us 
to genotype the selected variants in our SCZ cohort, in addition to the 
subjects with BD and control subjects.
The rare allele of rs754333774 was found only in individuals with 
BD or SCZ; in our own data and, this finding was not statistically 
significant. This variant was detected in a single individual from the 
Wellderly sample but was absent in a substantially larger number of 
individuals from the UK10K cohorts. Together the frequency of this 
variant in the combined UK10K cohorts and Wellderly sample was 
lower than that in our BD and SCZ case cohorts. This finding is intrigu-
ing but requires validation in large independent samples of subjects 
with BD and or SCZ and healthy controls. No support for a role for 
rs768049399 in BD (and/or SCZ) was found.
In order for microRNAs to regulate gene expression, they need to 
bind to a target region, normally in the 3ʹ UTR of a gene. It is important 
that nucleotides 2–8 of the miRNA have a perfect match with their 
target, and this region is defined as a seed region. The miRNA bind-
ing site and, more specifically, the seed regions are well conserved; 
they are more likely to reside within those targets in the transcrip-
tome with lower variant densities, especially target regions in which 
nucleotides have low mutation frequencies.41 Analysis of enrichment 
of GWS signals for miRNA genes and their putative target regions im-
plicated miR- 137 and its pathway in SCZ in different populations.42,43 
With the advent of WGS, it is therefore possible to implicate not only 
regions, but also specific variants, in disease. WGS data for 99 BD 
subjects were analyzed for possible variants in the miR- 708 binding 
sites predicted by Targetscan. This analysis identified four miR- 708 
binding site variants, each of which was located in brain- expressed 
genes, including APOC3 and SLC22A23. Both of these genes have 
been reported to be associated with the response to antipsychotic 
drug treatment. Variants in APOC3 have been implicated in variations 
of cholesterol and triglyceride levels in SCZ patients treated with 
clozapine and olanzapine;44 variants in SLC22A23 have been reported 
to be associated with QT prolongation in a GWAS of subjects with 
SCZ treated with quetiapine.45 However, comparison of the allele fre-
quency data of the four miR- 708 binding site variants between the 99 
WGS subjects with BD and those in reference databases suggested 
that none of the miR708 3 ʹUTR binding site variants were likely to be 
etiological. Indeed, analysis of imputed data from our own BD case–
control sample did not show evidence for an association for the two 
variants that were reliably imputed. One of the challenges of studying 
miRNAs is the complexity of miRNA-target gene networks. The study 
of these networks requires systematic computational prediction of 
miRNA-target gene interactions. However, there is a certain degree 
of imprecision in the predictions made by current miRNA target gene 
algorithms. This imprecision can be observed in the inconsistent pre-
diction scores that are obtained from the different algorithms. Most 
algorithms do not consider whether miRNA genes and their poten-
tial target are co-expressed and this could be an effective way of im-
proving predictions. Furthermore both miRNAs and their targets are 
located in areas of the genome that are not often covered by whole 
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exome sequencing. However, as larger scale WGS datasets become 
available, variation in 3’UTRs and intronic/intragenic regions will be 
better described, making it possible to begin to understand the func-
tional role of these regions.
4  | CONCLUSIONS
In summary, we report a single recurrent variant located close to in 
the miR- 708 gene that may have a role in susceptibility to BD and/
or SCZ. This finding awaits replication in independent SCZ and BD 
cohorts, as does a functional analysis of the potential consequences 
of this variant.
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